ZEISS Medical Technology Collaborates with Envision Health Technologies on Next-Generation Visual Function Testing

ZEISS Medical Technology Collaborates with Envision Health Technologies on Next-Generation Visual Function Testing

(IN BRIEF) ZEISS Medical Technology has entered into a strategic collaboration with Envision Health Technologies to advance virtual reality-based visual function testing for glaucoma care. The partnership combines ZEISS’ long-standing expertise in perimetry and visual field testing with Envision’s software-driven and gamified VR approach to digital eye health. Envision Health Technologies was founded by glaucoma surgeon Dr Lama A Al-Aswad and focuses on next-generation, data-driven solutions for vision-threatening diseases. The collaboration responds to growing demand for more accessible glaucoma screening, flexible workflows and patient-centred diagnostic technologies. ZEISS said the partnership reflects its commitment to clinician-driven innovation, while Envision said the agreement brings together software innovation with trusted market leadership in perimetry. The companies aim to help shape the future of VR-based visual function testing while maintaining a science-first and clinically rigorous approach.

(PRESS RELEASE) JENA, 19-Jun-2026 — /EuropaWire/ — ZEISS Medical Technology has announced a strategic collaboration with Envision Health Technologies to advance virtual reality-based visual function testing for glaucoma care.

The collaboration brings together ZEISS’ long-standing expertise in perimetry and visual field testing with Envision Health Technologies’ software-driven approach to digital eye health. The companies aim to support the development of patient-accessible, clinically grounded technologies that can help modernise glaucoma diagnostics and care workflows.

Envision Health Technologies was founded by glaucoma surgeon Dr Lama A Al-Aswad and focuses on next-generation digital solutions for vision-threatening diseases. Through the partnership, ZEISS and Envision will explore the potential of gamified virtual reality technology to make visual function testing more flexible, accessible and patient-centred, while maintaining a strong scientific and clinical foundation.

ZEISS said the collaboration comes at a time of growing demand for broader access to glaucoma screening and more adaptable workflow solutions. Healthcare providers are increasingly looking at portable and software-based approaches that can support visual function testing across different care settings.

Anuj Kalra, Head of Chronic Disease Management at ZEISS Medical Technology, said glaucoma care is evolving and clinicians need solutions that improve accessibility, flexibility and patient experience without reducing clinical confidence. He said the partnership with Envision Health Technologies reflects ZEISS’ commitment to practical, clinician-driven innovation that can help expand access to visual function testing.

Dr Lama A Al-Aswad, Founder and CEO of Envision Health Technologies, said the future of visual function testing should be more accessible, flexible and patient-centred while remaining grounded in clinical rigour. She said working with ZEISS creates an opportunity to combine software innovation with decades of trusted leadership in perimetry.

The collaboration is intended to help shape the future direction of virtual reality-based perimetry and visual function testing. By combining ZEISS’ long-term innovation strategy in visual field testing with Envision’s expertise in virtual reality and software-driven diagnostics, the companies aim to support more practical solutions for real-world glaucoma care.

ZEISS noted that product availability, regulatory approval, labelling and instructions can vary by market, and product specifications may change as technologies continue to develop.

Brief profile

Carl Zeiss Meditec AG (ISIN: DE0005313704), which is listed on the TecDAX and SDAX of the German stock exchange, is one of the world’s leading medical technology companies. The Company supplies innovative technologies and application-oriented solutions designed to help doctors improve the quality of life of their patients. The Company offers complete solutions, including implants and consumables, to diagnose and treat eye diseases. The Company creates innovative visualization solutions in the field of microsurgery. With 5,784 employees worldwide, the Group generated revenue of €2,228m in fiscal year 2024/25 (to 30 September).

The Group’s head office is located in Jena, Germany, and it has subsidiaries in Germany and abroad; more than 50 percent of its employees are based in the USA, Japan, Spain and France. The Center for Application and Research (CARIn) in Bangalore, India and the Carl Zeiss Innovations Center for Research and Development in Shanghai, China, strengthen the Company’s presence in these rapidly developing economies. Around 39 percent of Carl Zeiss Meditec AG’s shares are in free float. Approx. 59 percent are held by Carl Zeiss AG, one of the world’s leading groups in the optical and optoelectronic industries.

For more information visit our website at www.zeiss.com/med

Media Contacts:

Sebastian Frericks
Head of Group Finance & Investor Relations
Carl Zeiss Meditec AG
tel:+49 3641  220 116
investors.med@zeiss.com

Frank Smith
Head of Global Communications Ophthalmology
Carl Zeiss Meditec Inc.
tel:+49  3641  220 331
press.med@zeiss.com

SOURCE: ZEISS